Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK101
- Development stage
- Preclinical
- Lead developer
- NKore BioTherapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NK101 (allogeneic super-charged natural killer cells) is an off-the-shelf, non-engineered cellular immunotherapy being developed by NKore BioTherapeutics, based on technology originated by Dr. Anahid Jewett at the University of California, Los Angeles (UCLA). The therapy consists of healthy donor-derived (allogeneic) natural killer (NK) cells that are expanded and activated ('supercharged') in vitro using a proprietary co-culture method involving osteoclasts and a probiotic formulation (sAJ2). This process enhances the cytotoxicity, persistence, and cytokine secretion (such as IFN-gamma and TNF-alpha) of the NK cells, enabling them to effectively target and eliminate cancer stem cells (CSCs) and poorly differentiated tumor cells within the immunosuppressive tumor microenvironment. NK101 is being evaluated for the treatment of various solid tumors and hematological malignancies, including glioblastoma, pancreatic cancer, melanoma, oral cancer, and colorectal cancer.
- Other names
- allogeneic super-charged natural killer cellsallogeneic supercharged natural killer cellssNK cellssuper-charged NK cellssupercharged NK cellssupercharged natural killer cells
Beyond the preview
Go deeper on NK101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK101.